#Denmark #Biomarker Assay #Nordic Bioscience #Herlev #Endotrophin

Nordic Bioscience Unveils the nordicEndotrophin Assay

In a significant advancement in biomarker diagnostics, Nordic Bioscience has introduced the nordicEndotrophin™, a fully automated high-precision assay that quantifies the intact 77-amino-acid Endotrophin signaling hormone. This breakthrough product was developed in the CAP/CLIA certified Nordic Bioscience laboratory and shows promising prognostic capabilities in the realms of fibrosis and cancer research.

Following the successful integration of existing assays like nordicPRO-C6™ and nordicPRO-C3™, the introduction of nordicEndotrophin™ creates a comprehensive platform for assessing the fibro-inflammatory responses associated with chronic diseases, including cardiovascular and metabolic disorders. The nordicEndotrophin™ assay excels in enhancing risk stratification and pharmacodynamic monitoring for various conditions, especially emphasizing the critical role Endotrophin plays in patient outcomes.

What is Endotrophin?

Endotrophin was first identified in 2012 as a hormone derived from type VI collagen; its role as a significant factor in fibroblast activation reveals its connection to fibrotic processes. Notably, fibrotic conditions contribute to around 40% of mortality rates in Western countries, with obesity acting as a catalyst, exacerbating fibroblast activation in various organs, including the liver, kidneys, and heart. Studies have illustrated that a two-fold increase in circulating Endotrophin levels correlates with a 100% rise in mortality risk, emphasizing the need for accurate quantification methods.

The recent addition of the nordicEndotrophin™ assay to Nordic Bioscience's portfolio not only reinforces their commitment to innovation but also solidifies the linkage between wound healing and fibrotic progression in chronic disease management. It stands as a crucial tool for researchers aiming to develop precision medicine strategies that account for this hormone’s deleterious effects.

Enhancing Clinical Assessments

The new assay offers increased specificity compared to Nordic Bioscience's first assay, PRO-C6, which measures the total pool of type VI collagen. By focusing exclusively on the intact 77-amino-acid Endotrophin, the nordicEndotrophin™ assay provides additional prognostic insights, complementing the information gathered from other assays like PRO-C6. This specificity can significantly enhance patient stratification in clinical settings, especially for those suffering from fibrotic diseases, obesity, and autoimmune conditions.

Dr. Morten Karsdal, CEO of Nordic Bioscience, noted, “Endotrophin is a significant prognostic biomarker. In a pivotal study concerning HFpEF patients, our Endotrophin and PRO-C6 assays exhibited superior accuracy compared to NT-proBNP in predicting mortality and hospitalization risk.” The collaborative use of these assays will provide unprecedented capabilities for refining treatments and improving patient care.

Availability and Future Prospects

Available through Nordic Bioscience's state-of-the-art laboratory in Herlev, Denmark, the nordicEndotrophin™ high-precision assay is designed for high-throughput platforms, ensuring efficient and accurate results. This advancement encourages clients to employ the assay alongside the nordicPRO-C3™ and nordicPRO-C6™, enhancing comparative assessments that can lead to more informed decisions in both anti-fibrotic and oncology clinical trials.

In conclusion, the introduction of nordicEndotrophin™ marks a pivotal moment for Nordic Bioscience, as they continue to lead the field of biomarker development. The ability to measure Endotrophin meticulously will pave the way for innovative approaches to tackle fibrotic diseases and improve patient outcomes significantly, showcasing the potential of precision medicine in today’s healthcare landscape.

For more details about Nordic Bioscience and their innovative assays, visit Nordic Bioscience.